Literature DB >> 15653312

Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes.

Eleni Zika1, Jenny P-Y Ting.   

Abstract

Recent advances have shown the crucial role of histone-modifying enzymes in controlling gene activation and repression. This led to the 'histone code' hypothesis, which proposes that combinations of histone modifications work in concert to affect specific gene expression. Mounting evidence suggests that the class II transactivator modulates promoter accessibility by coordinating the recruitment of chromatin modifiers in a time-dependent fashion. MHC-II expression is exquisitely controlled by these highly specific, coordinated and dynamic interactions at the promoter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653312     DOI: 10.1016/j.coi.2004.11.008

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  39 in total

1.  NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.

Authors:  Yikun Yao; Yalong Wang; Fuxiang Chen; Yin Huang; Shu Zhu; Qibin Leng; Hongyan Wang; Yufang Shi; Youcun Qian
Journal:  Cell Res       Date:  2012-04-10       Impact factor: 25.617

2.  New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.

Authors:  Michal Krawczyk; Krzysztof Masternak; Madeleine Zufferey; Emmanuèle Barras; Walter Reith
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

Review 3.  NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.

Authors:  Jeanette M Wilmanski; Tanja Petnicki-Ocwieja; Koichi S Kobayashi
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

4.  An MHC class II restriction bias in CD4 T cell responses toward I-A is altered to I-E in DM-deficient mice.

Authors:  Paula R Menges; Scott A Jenks; Elizabeth K Bikoff; David R Friedmann; Zackery A G Knowlden; Andrea J Sant
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 5.  The evolving role of semaphorins and plexins in the immune system: Plexin-A1 regulation of dendritic cell function.

Authors:  Brian P O'Connor; Jenny P-Y Ting
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Dysregulated TLR3-dependent signaling and innate immune activation in superoxide-deficient macrophages from nonobese diabetic mice.

Authors:  Maria C Seleme; Weiqi Lei; Ashley R Burg; Kah Yong Goh; Allison Metz; Chad Steele; Hubert M Tse
Journal:  Free Radic Biol Med       Date:  2012-02-04       Impact factor: 7.376

7.  Epigenomic elements enriched in the promoters of autoimmunity susceptibility genes.

Authors:  Mikhail G Dozmorov; Jonathan D Wren; Marta E Alarcón-Riquelme
Journal:  Epigenetics       Date:  2013-11-08       Impact factor: 4.528

8.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

9.  Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells.

Authors:  Beatriz Suárez-Alvarez; Ramón M Rodriguez; Vincenzo Calvanese; Miguel A Blanco-Gelaz; Steve T Suhr; Francisco Ortega; Jesus Otero; Jose B Cibelli; Harry Moore; Mario F Fraga; Carlos López-Larrea
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

10.  Role of plasmacytoid dendritic cells for aberrant class II expression in exocrine glands from estrogen-deficient mice of healthy background.

Authors:  Rieko Arakaki; Ai Nagaoka; Naozumi Ishimaru; Akiko Yamada; Satoko Yoshida; Yoshio Hayashi
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.